Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

PharmaLex strikes up AI collaboration with Volv

The duo will develop pharmacovigilance products and services

NDA Group appoints new vice president

Dr Werner Van den Eynde will also lead its advisory board

- PMLiVE

Ceuta Holdings acquires Creative Leap

The comms agency will continue to act as an independent business

- PMLiVE

Building a creative marketing consultancy: how we’ve transitioned into a full service global team

In this Q&A, James Atherton, Vice President and Managing Consultant at our New York office, reveals how our NYC and London offices work together and why having a creative services...

Blue Latitude Health

- PMLiVE

Vas Narasimhan takes top Novartis job on Jimenez departure

The soon-to-be CEO will take over at a time when the company has a strong pipeline

- PMLiVE

Merck mulls sale of consumer health division

The German pharma group will focus on its science and technology businesses

- PMLiVE

New medical media agency launched in UK

Method Medical Media will focus on marketing and social media

Pegasus strengthens its Pharma and Life Sciences division

Appoints three new team members to join its Northern base

Can we ‘outsmart’ smartphone addiction by using it to develop effective health apps?

Are you guilty of repeatedly checking your phone 24/7? Our new blog explores what makes them so addictive and how understanding this may help us develop more effective health apps.

Say Communications

- PMLiVE

Lucid welcome their graduate Customer Experience Managers

Lucid has had an incredibly busy summer attending recruitment fairs all across the country to find the finest graduate talent for their Futures Executive Programme. As part of its graduate...

Lucid Group Communications Limited

- PMLiVE

Janssen launches UK blood cancer awareness campaign

The pharma group join forces with designer to set up ‘giant’ names in London

- PMLiVE

Dismay as NICE turns down first-line use of AZ’s Faslodex

Says evidence isn’t convincing for use in post-menopausal women

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links